SCHEMBL6798405

SCHEMBL6798405

COC(=O)/C=C/c1cccc(-n2c(=O)c(Cc3ccccc3)nc3cccnc32)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.46
BTK Q06187 1/20 0.46
ITK Q08881 1/20 0.46
KMT2A Q03164 2/20 0.44
KDM4E B2RXH2 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NQO1 P15559 1/20 0.43
ALDH1A1 P00352 5/20 0.40
CYP1A2 P05177 5/20 0.40
CYP3A4 P08684 5/20 0.40
CYP2C9 P11712 5/20 0.40
TSHR P16473 5/20 0.40
CYP2C19 P33261 5/20 0.40
USP2 O75604 4/20 0.40
GLA P06280 1/20 0.40
AKT1 P31749 1/20 0.40
PDE4B Q07343 2/20 0.40
PDE4D Q08499 2/20 0.40
CYP2D6 P10635 3/20 0.39
HSD17B10 Q99714 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6798410 1.00 EGFR (0.46) EGFRBTKITKKMT2AKDM4E
SCHEMBL6804117 0.92 EGFR (0.43) EGFRBTKITKKMT2AKDM4E
SCHEMBL6804121 0.92 EGFR (0.43) EGFRBTKITKKMT2AKDM4E
SCHEMBL8065833 0.89 KDM4E (0.41) EGFRBTKITKKMT2AKDM4E
SCHEMBL8065829 0.89 KDM4E (0.41) EGFRBTKITKKMT2AKDM4E
SCHEMBL7487766 0.89 KDM4E (0.41) EGFRBTKITKKMT2AKDM4E
SCHEMBL6798318 0.88 CYP3A4 (0.47) EGFRBTKITKSMN1; SMN2ALDH1A1
SCHEMBL6798326 0.88 CYP3A4 (0.47) EGFRBTKITKSMN1; SMN2ALDH1A1
SCHEMBL6798998 0.87 ALDH1A1 (0.43) EGFRBTKITKKMT2AKDM4E
SCHEMBL6799005 0.87 ALDH1A1 (0.43) EGFRBTKITKKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727245-B2 4-(HETERO)ARYL-3-OXO-3,4-DIHYDROPYRIDO(2,3-B)PYRAZINE DERIVATIVES; PROPHYLACTIC OR THERAPEUTIC TREATMENT OF PHOSPHODIESTERASE IV AND TUMOR NECROSIS FACTOR MEDIATED DISEASES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-04-27 US disclosed
EP-0770079-B1 HETEROBICYCLIC DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2003-02-12 EP disclosed
US-6426345-B1 PHOSPHODIESTERASE INHIBITORS; ANTIINFLAMMATORY AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-30 US disclosed
EP-0920867-A1 Pyrido[2,3-a]pyrazine derivatives as PDE-IV and TNF inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-06-09 EP disclosed
WO-1996001825-A1 HETEROBICYCLIC DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-01-25 WO disclosed